Iovance Biotherapeutics (IOVA) forecasts revenue of $350 million to $370 million in 2026, representing 36% year-over-year growth. This growth is driven by the expansion of its drug Amtagvi into new cancer indications such as non-small cell lung cancer, endometrial cancer, and sarcoma, as well as entry into global markets. The company benefits from a more receptive FDA that may allow accelerated approvals based on single-arm trial data, potentially speeding up drug development. IOVA also expects its current cash reserves to fund operations into early 2028, with the option to raise additional funds if needed through its at-the-market facility.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
